-
Editorials
Steatotic liver disease: Know your enemies
- Lung-Yi Mak
- Clin Mol Hepatol. 2024;30(2):171-173.
-
Reviews
The role of different viral biomarkers on the management of chronic hepatitis B
- Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen
- Clin Mol Hepatol. 2023;29(2):263-276.
-
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective
- Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen
- Clin Mol Hepatol. 2023;29(2):217-229.
-
Screening strategy for non-alcoholic fatty liver disease
- Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
- Clin Mol Hepatol. 2023;29(Suppl):S103-S122.
-
Correspondences
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
- Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
- Clin Mol Hepatol. 2023;29(1):191-193.
-
Original Articles
Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
- Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen
- Clin Mol Hepatol. 2023;29(1):146-162.
-
Reviews
RNA interference as a novel treatment strategy for chronic hepatitis B infection
- Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
- Clin Mol Hepatol. 2022;28(3):408-424.